Effects of cisplatin on different haemopoietic progenitor cells in mice

Open Access
Publisher Website
Google Scholar
Abstract
The effects of cisplatin on marrow hemopoietic progenitor cells, WBC [white blood cells] and RBC [red blood cells] were measured and compared in F1 (CBA .times. C57BL) female mice. Dose/survival curves of cisplatin for CFU-S [pluripotential stem cell], CFU-C [granulocytic progenitor cell] and BFU-E [erythropoietic burst-forming cell] were found to be simply exponential, indicating that the effect of the drug has no cell-cycle dependency. BFU-E also appeared significantly (P < 0.001) more sensitive to cisplatin than CFU-S and CFU-C. After a single dose of 12 mg/kg of cisplatin, WBC, MNC [mononuclear cell] and CFU-E were seen to be markedly less reduced and to recover much earlier than CFU-C, and particularly BFU-E and CFU-S. Results suggest that the drug is more toxic for earlier hemopoietic progenitor cells than for the more mature cells, and that the latter are not reliable parameters for complete hemopoietic recovery in mice after treatment with this agent. In the animals treated, there was also a subsequent significant decrease of the RBC count, accompanied by a marked increase of the marrow CFU-E concentration. Possible underlying mechanisms (e.g., alterations of RBC after exposure to cisplatin) were discussed. [Cisplatin (cis-diamminedichloroplatinum II) is an effective antineoplastic agent.].